Why biosimilars will have a smaller competitive edge than generics

Journal of Health Care Finance

Volumn 35, Issue 2, 2008, Pages 84-95

  Blackstone, Erwin A ^a   Fuhr Jr , Joseph P ^b,c  

^a TEMPLE UNIVERSITY   (United States)

^b WIDENER UNIVERSITY   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Biopharmaceuticals; Biosimilars; Generic competition; Innovation; Patents; R D

Indexed keywords

GENERIC DRUG;

BIOTECHNOLOGY; CAPITAL; DRUG COST; DRUG INDUSTRY; DRUG MANUFACTURE; EUROPEAN UNION; HEALTH CARE FINANCING; HEALTH CARE POLICY; MARKETING; PROSPECTIVE PRICING; REIMBURSEMENT; REVIEW; UNITED STATES;

EID: 58149389419     PISSN: 10786767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Standard and Poor's, "Biotechnology," Industry Surveys, July 5, 2007, p. 26.
2. Ibid., p. 17.
3. Ibid., p. 2.
4. Gary P. Pisano, Science Business, Harvard Business School Press, Boston, MA, 2006, p. 112.
5. Ryan McBride, "Biotech toots own horn about nearing profitability," Mass High Tech: The Journal of New England Technology, May 30, 2008, available at http://www.bizJournals.com/ masshightech/stories/2008/06/02/news, accessed June 2, 2008.
6. Susan M. Sensabaugh, "Biological Generics: A business case," Journal of Generic Medicines, (2007) 4, 186-199 published online February 20, 2007.
7. Standard and Poors, "Biotechnology," Industry Survey, Feb. 14, 2008, p. 25.
8. Ibid., p. 25.
9. These figures come from Sensabaugh.
10. This material comes from Basant G. Sharma, "Manufacturing Challenges for Biosimilars - The Process Defines the Product," EJHPP Practice, vol. 13, 2007, pp. 54-55.
11. Ibid., p. 56.
12. Quoted in Pamela Jones Harbour "Competitive Implications of Generic Biologies," Remarks of Federal Trade Commissioner Harbour before AGA Sections on Antitrust and Intellectual Property Law, Intellectual Property Antitrust: Strategic Choices Evolving Standards, and Practical Solutions, San Francisco, CA, June 14, 2007, p. 6.
13. Simon D. Roger and Ashraf Mikhail, "Biosimilars: Opportunity or Cause for Concern?" J Phar Pharmaceut Sci, Vol. 10, 2007, pp. 405-410.
14. Genentech, Inc., Form 10-K for the fiscal year ended Dec. 31, 2007 p. 16.
15. Amgen, Inc., Form 10-K for the fiscal year ended Dec. 31, 2007, p. 54.
16. Henry G. Grabowski, David B. Ridley, and Kevin A. Schulman, "Entry and Competition in Generic Biologicals," Managerial and Decision Economies, 2007, p. 11.
17. Ibid., p. 11.
18. Ibid., p. 11.
19. Mark J. Belsey, Laura M. Harris, Romita R. Das, and Joanna Cherthow, "Biosimilars, intial excitement gives way to reality," News and Analysis, Nature Reviews, Drug Discoveres, vol. 5, July 2006. Obtained from www.Nature.com/pdpfinder/10.1038/nrd/2093.
20. Jo Pisani and Yann Bogduelle, "Opportunities and Barriers in the Biosimilar Market: Evolution or Revolution for Generic Companies?" Price Waterhouse Coopers, undated.
21. S&P, "Biotechnology," p. 29.
22. Gina Kolata and Andrew Pollack, "Costly Cancer Drug Offers Hope, but Also a Dilemma," New York Times, July 6, 2008.
23. S&P, "Biotechnology," p. 29.
24. Steve Usdin, "Firing up for FOBs," Biocentury, from the Bernstein Report on Biobusiness, Jan. 29, 2007, p. 2.
25. Todd Wallock, "FDA Rejects Genzyme request for Myozyme," Boston Globe, Apr. 22, 2008 obtained from http://www.boston.com/ business/heathcare/articles/2008/04/22fda_rejects_genzyme_request-fo.../est, accessed Apr. 23, 2008.
26. Amgen 10-K, p. 38.
27. Ibid., p. 38.
28. Ibid., p. 39.
29. Nuala Moran, "Fractured European market undermines biosimilar launches," Nature Biotechnology, 26, 5-6, 2008, p. 2.
30. H. Mellstedt, D. Niedewieser, and H. Ludwig, "The Challenge of Biosimilars," Annals of Oncology, 2007, p. 4.
31. Generic Biopharmaceuticals, p.3, http://www.biopharma.com/generics/.
32. Moran, p. 2.
33. Ibid.
34. Ibid.
35. Elisbethann Wright, "Generic and biosimilar medicinal products in the European Union," Chemistry Today, Mar./Apr. 2007, p. 6.
36. Pete Mansell, "Omnitrope Penn 5 ups the convenience factor," In-Pharma, Mar. 18, 2008, p. 2.
37. Biosimilars - Breakthrough for the European pharma industry?" BioPro, May 2, 2007, p. 3.
38. Sharma, p. 54.
39. Emilie Raymond, "Dr. Reddy's Bets High on Biosimilars," In-Pharma, Aug. 30, 2007, p. 1.
40. Ibid.
41. Nalini Motwani, "Biosimilars Jumpstart Biotech in India," Apr. 15, 2007, p. 4.
42. Ibid, p. 5.
43. Alex D. Kanareh, "The Launch of the Biosimilar Product," Bioscienceworld, 2006, p. 2.
44. Gary C. Messplay and Colleen Heisey, "Follow-on Biologies: The Evolving Regulatory Landscape," Bio-Executive International, May 2006, p. 42.
45. Simon D. Roger and Ashraf Mikhail, "Biosimilars: Opportunity or Cause for Concern?" Journal of Pharma Pharmaceut Sci, 2007, p. 4.
46. Congressional Budget Office, "S. 1695, Biologics Price Competition and Innovation Act of 2007," June 25, 2008, p. 1.